Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Clinical Effect and Mechanism of Fuzheng Tongfu Jiedu Prescription Regulating Cell Pyrodeath in the Treatment of Gastrointestinal Dysfunction in Sepsis Based on mtDNA/NLRP3/Caspase-1/GSDMD Signaling Pathway

NCT06933238 is registered in ClinicalTrials.gov with Dongzhimen Hospital, Beijing as lead sponsor.

NCT NCT06933238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06933238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Clinical Effect and Mechanism of Fuzheng Tongfu Jiedu Prescription Regulating Cell Pyrodeath in the Treatment of Gastrointestinal Dysfunction in Sepsis Based on mtDNA/NLRP3/Caspase-1/GSDMD Signaling Pathway
Lead sponsor
Dongzhimen Hospital, Beijing
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 25, 2025
Completion date
June 30, 2026
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal dysfunction, sepsis abdominal, traditional chinese medicine